Exchange: OSE Industry: Pharmaceuticals, Biotechnology & Life Sciences
Current Signal: BUY (auto-tracking)
1.09% NOK0.167
Europe/Oslo / 25 apr 2024 @ 09:25
FUNDAMENTALS | |
---|---|
MarketCap: | 448.47 mill |
EPS: | -0.550 |
P/E: | -0.300 |
Earnings Date: | May 29, 2024 |
SharesOutstanding: | 2 688.69 mill |
Avg Daily Volume: | 43.67 mill |
RATING 2024-04-24 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | |
Gr.Profit | n/a | n/a | ||||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.300 | sector: PE 22.86 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.01x |
Company: PE -0.300 | industry: PE 33.94 |
DISCOUNTED CASH FLOW VALUE |
---|
NOK0.189 (13.56%) NOK0.0226 |
Date: 2024-04-25 |
Expected Trading Range (DAY) |
---|
NOK 0.147 - 0.183 ( +/- 10.90%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | NOK0.167 (1.09% ) |
Volume | 2.25 mill |
Avg. Vol. | 43.67 mill |
% of Avg. Vol | 5.16 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:40 | sell | NOK0.306 | N/A | Active |
---|
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.